A group from Nagoya University in Japan has developed a simple, accurate, and sensitive method for measuring polysialic acid, ...

Sanofi (NASDAQ: SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

Sanofi's antibody riliprubart has received orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...

The companies place the partnership’s value at up to $1.5 billion, including an undisclosed up-front payment in the ...

Explore the latest on VYVGART HYTRULO's FDA safety signal and transition challenges. Learn why argenx's balanced risks keep ...

Japanese MHLW grants orphan drug designation to Sanofi’s riliprubart for chronic inflammatory demyelinating polyneuropathy: Paris Tuesday, July 1, 2025, 09:00 Hrs [IST] The Mini ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

One step at a time, those who are diagnosed with rare neuropathic conditions such as GBS or CIDP prove it's possible to get ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy . Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a ...

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy Two phase 3 studies are currently underway testing riliprubart in people with CIDP as ...